Elusys awarded $50.2 million for anthrax treatment

Elusys Therapeutics to receive additional funding from US Government

Elusys Therapeutics, a biopharmaceutical company, announced this week that it has received additional funding from the US government for the development of an investigational agent for treating anthrax.

Full story here.

Our Current Sponsors

  • 908 Devices
  • Airboss
  • Argon
  • Avon
  • Battelle
  • Biofire Idaho
  • Bruker
  • Bw Tek
  • Cap Force 1 Decon 01
  • CQC
  • Cristanini
  • Decon Seven Systems
  • DQE
  • Dxterity
  • Emergent Biosol
  • Endeavor Roborics
  • Ecotest
  • Federal Resources
  • First Line Technology
  • Flir
  • Futurtech
  • Hameln
  • Metrohm Raman
  • NBC sys
  • Proengin
  • Qinetiq
  • RSDecon
  • Tex Shield
  • Wl Gore